<DOC>
	<DOCNO>NCT00001016</DOCNO>
	<brief_summary>To determine safety effectiveness investigational drug trimetrexate ( TMTX ) leucovorin rescue ( LCV ) treatment Pneumocystis carinii pneumonia ( PCP ) patient AIDS , HIV positive , high risk HIV infection , demonstrate serious adverse effect conventional therapy PCP . The drug usually use treat PCP AIDS patient ( trimethoprim / sulfamethoxazole pentamidine ) discontinue many patient severe adverse effect . Currently proven alternative drug . TMTX choose trial find active PCP organism laboratory test . In preliminary trial , TMTX combination LCV effective PCP few less severe adverse effect .</brief_summary>
	<brief_title>A Treatment Protocol Use Trimetrexate With Leucovorin Rescue AIDS Patients With Pneumocystis Carinii Pneumonia Serious Intolerance Approved Therapies</brief_title>
	<detailed_description>The drug usually use treat PCP AIDS patient ( trimethoprim / sulfamethoxazole pentamidine ) discontinue many patient severe adverse effect . Currently proven alternative drug . TMTX choose trial find active PCP organism laboratory test . In preliminary trial , TMTX combination LCV effective PCP few less severe adverse effect . AMENDED : 08/01/90 . As August 31 , 1989 , 437 patient enrol uncontrolled study trimetrexate PCP:214 TX 301/ACTG 0=039 ( trimetrexate patient intolerant approved therapy ) 223 NS 401 ( trimetrexate patient refractory approved therapy ) . The analysis overall response rate , stringently define receive least 14 day trimetrexate alive follow-up 1 month completion therapy , reveal 84/159 intolerant patient 48/160 refractory patient respond , rate 53 percent 30 percent , respectively . These response rate include individual receive least one dose trimetrexate . Of 111 patient ventilator-dependent study entry , 18 complete course therapy alive month later , response rate 16 percent . All ventilate patient die . The common severe ( grade 3 4 ) toxicity : transaminase elevation ( great 5 x normal ) 94 patient , anemia ( le 7.9 g/dl ) 109 , neutropenia ( less 750 cells/mm3 ) 58 , fever ( great 40 degree C ) 37 , thrombocytopenia ( le 50,000 platelets/mm3 ) 27 . Toxicity require discontinuation therapy approximately 5 percent patient . Original design : Patients enter study give TMTX day 21 day LCV 4 time day ( every 6 hour ) 24 day . Doses determine body size . Both drug give intravenous infusion , LCV may give orally first 10 day . Doses adjust side effect , low white blood cell count , severe . During 21-day trial , zidovudine ( AZT ) may use possible increase bone marrow toxicity . AZT may resume soon administration TMTX LCV complete . After treatment TMTX , patient may treat drug prevent recurrence PCP discretion his/her physician .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Blood pressure medication . Concurrent Treatment : Allowed : Blood product . Ventilatory support . Patients must follow : Diagnosis Pneumocystis carinii pneumonia ( PCP ) . Be HIV positive ELISA , HIV culture , p24 antigenemia ; member identify risk group . Intolerant trimethoprim / sulfamethoxazole ( TMP / SMX ) . Intolerant pentamidine . Prior Medication : Allowed : Trimethoprim / sulfamethoxazole trial . Pentamidine trial . Myelosuppressive agent . Nephrotoxic agent . Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients meet inclusion criterion exclude . Concurrent Medication : Excluded : Myelosuppressive agent . Nephrotoxic agent . Other investigational drug include highdose steroid ( exceed physiologic replacement dos ) . Patients meet inclusion criterion exclude .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1993</verification_date>
	<keyword>Trimetrexate</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Quinazolines</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>